tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Buy Rating for vTv Therapeutics: Promising Potential of Cadisegliatin in Type 1 Diabetes Treatment
PremiumRatingsBuy Rating for vTv Therapeutics: Promising Potential of Cadisegliatin in Type 1 Diabetes Treatment
2M ago
vTv Therapeutics reports Q1 EPS (77c), consensus (81c)
Premium
The Fly
vTv Therapeutics reports Q1 EPS (77c), consensus (81c)
2M ago
vTv Therapeutics reports reinitiation of screening in CATT1 Phase 3 trial
Premium
The Fly
vTv Therapeutics reports reinitiation of screening in CATT1 Phase 3 trial
2M ago
vTv Therapeutics Resumes Phase 3 Trial for Cadisegliatin
PremiumCompany AnnouncementsvTv Therapeutics Resumes Phase 3 Trial for Cadisegliatin
4M ago
vTv Therapeutics reports Q4 EPS (55c) vs ($1.67) last year
Premium
The Fly
vTv Therapeutics reports Q4 EPS (55c) vs ($1.67) last year
4M ago
Biotech Alert: Searches spiking for these stocks today
Premium
The Fly
Biotech Alert: Searches spiking for these stocks today
4M ago
vTv Therapeutics CFO Steven Tuch to Resign
PremiumCompany AnnouncementsvTv Therapeutics CFO Steven Tuch to Resign
5M ago
vTv Therapeutics Highlights Progress on Diabetes Treatment
Premium
Company Announcements
vTv Therapeutics Highlights Progress on Diabetes Treatment
6M ago
vTv Therapeutics initiated with a Buy at Alliance Global Partners
Premium
The Fly
vTv Therapeutics initiated with a Buy at Alliance Global Partners
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100